Skip to main content

Levy Noah G.'s Form 4 filing

Merrimack Pharmaceuticals Inc (MACK) · filed Jun 16, 2022

Accession no.
0000899243-22-022785
Filed
Jun 16, 2022, 4:05 PM ET
Trade date
Jun 14-15, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $123.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Levy Noah G.CIK 0001788608Director, Other: See remarks
Newtyn Partners, LPCIK 0001548707Other: See Remarks
Newtyn TE Partners, LPCIK 0001548709Other: See Remarks
Newtyn Management, LLCCIK 0001569241Other: See Remarks
Newtyn Capital Partners, LPCIK 0001789643Other: See Remarks
Ledo Capital, LLCCIK 0001789647Other: See Remarks

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 14, 2022Common StockPPurchaseAcquired+11,977$5.17+$61,960.611,010,515Indirect
Jun 14, 2022Common StockPPurchaseAcquired+8,961$5.17+$46,357.94740,120Indirect
Jun 15, 2022Common StockPPurchaseAcquired+1,659$5.37+$8,902.031,012,174Indirect
Jun 15, 2022Common StockPPurchaseAcquired+1,241$5.37+$6,659.08741,361Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)